Merck & Co. (MRK) Stock Price, News & Analysis

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a research-intensive biopharmaceutical company in the pharmaceutical preparation manufacturing industry. The company focuses on developing and delivering medicines and vaccines that address serious human and animal health conditions. According to its public statements, Merck is unified around a purpose of using science to save and improve lives and has been bringing forward medicines and vaccines for more than 130 years.

Merck develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disease, cancer and infectious diseases. Within oncology, the firm’s immuno-oncology platform is a major contributor to sales, led by KEYTRUDA (pembrolizumab), an anti–PD-1 therapy. Merck also has a substantial vaccine business, including vaccines aimed at preventing pediatric diseases and GARDASIL for human papillomavirus, and it sells animal health-related drugs through Merck Animal Health, which offers veterinary pharmaceuticals, vaccines and health management solutions.

Merck’s oncology activities are illustrated by its extensive KEYTRUDA clinical program. Company disclosures note that there are more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings, and that Merck has what it describes as the industry’s largest immuno-oncology clinical research program. KEYTRUDA is being studied alone and in combinations, including in non-small cell lung cancer (NSCLC), urothelial cancer and muscle-invasive bladder cancer (MIBC), with trials such as KEYNOTE-B15 and the KANDLELIT series evaluating combinations with agents like Padcev (enfortumab vedotin-ejfv) and calderasib (MK-1084).

Beyond oncology, Merck is active in cardiovascular and metabolic disease, as reflected in its work on enlicitide, a novel oral PCSK9 inhibitor candidate designed to lower LDL cholesterol. The company has also entered into a historic agreement with the U.S. government regarding access and pricing for certain prescription medicines, including JANUVIA (sitagliptin), JANUMET and JANUMET XR (sitagliptin and metformin HCl), and a planned direct-to-patient program for enlicitide decanoate following potential FDA approval.

Merck’s pipeline spans additional therapeutic areas. In neuroscience, it is advancing candidates for Alzheimer’s disease, including MK-2214, a novel antibody targeting phosphorylated tau that has received U.S. FDA Fast Track Designation, and MK-1167, an investigational oral positive allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Early clinical data for these candidates are informing ongoing Phase 2 trials in people with Alzheimer’s disease.

In pulmonary arterial hypertension (PAH), Merck is developing WINREVAIR (sotatercept-csrk), an activin signaling inhibitor. WINREVAIR is approved in the United States for adults with PAH (WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class and to reduce the risk of clinical worsening events, and it has an approved indication in the European Union with an application under review for an expanded use based on the Phase 3 ZENITH trial. The company notes that WINREVAIR is the first activin signaling inhibitor therapy approved to treat PAH in the EU and is approved in more than 50 countries.

Merck also maintains a significant presence in animal health. Merck Animal Health, a division of Merck & Co., Inc., develops veterinary pharmaceuticals, vaccines and health management solutions for veterinarians, farmers, producers, pet owners and governments. Recent activity includes the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 (fluralaner topical solution), a pour-on isoxazoline product for the prevention and treatment of infestations caused by New World screwworm larvae and for the treatment and control of cattle fever tick in specified cattle populations.

The company’s business model is centered on research, clinical development, regulatory approval and commercialization of human and animal health products. Merck describes itself as aspiring to be the premier research-intensive biopharmaceutical company in the world and emphasizes long-term investment in U.S.-based manufacturing and R&D. It has publicly stated that it has invested tens of billions of dollars in U.S. manufacturing and R&D over recent years and has committed to additional multiyear capital and research spending to support domestic production and innovation.

Merck’s capital markets activities include issuing notes under its automatic shelf registration statement on Form S-3ASR. Recent Form 8-K filings describe underwritten public offerings of multiple series of notes with maturities ranging from 2027 to 2065, issued under an indenture dated January 6, 2010. These offerings illustrate the company’s use of long-term debt financing as part of its capital structure, alongside its common stock listed on the New York Stock Exchange under the symbol MRK.

The company has also announced a multiyear optimization initiative and a 2025 restructuring program intended to position Merck for its next chapter of growth. According to its July 2025 Form 8-K, this program includes eliminating certain positions in sales, administrative and research and development organizations, reducing its global real estate footprint and continuing to optimize its manufacturing network. Merck expects the program to generate significant annual cost savings by the end of 2027, which it plans to reinvest into strategic growth areas of the business.

Merck grows through internal R&D and business development. A recent example is its acquisition of Cidara Therapeutics, Inc., through a cash tender offer followed by a planned merger, after which Cidara is expected to become a wholly owned subsidiary and its common stock will no longer be listed on the Nasdaq Global Market. This transaction brings CD388, a potentially first-in-class, long-acting antiviral candidate designed to prevent symptomatic influenza in individuals at higher risk of complications, into Merck’s expanding respiratory portfolio.

Across its operations, Merck emphasizes responsible business practices, noting that it fosters a diverse and inclusive global workforce and operates with the goal of enabling a safe, sustainable and healthy future for people and communities. The company highlights its long-standing role in delivering medicines and vaccines for human and animal health and its focus on advancing prevention and treatment of diseases through research-driven innovation.